Humanetics Corporation and Pharmaceutics International Inc. are partnering to support a clinical trial of BIO 300 in COVID-19 patients.   The study will focus on patients who were treated for severe COVID-19, discharged from the hospital, and continue to recover at home. These patients face the possible risk that their respiratory complications will continue to progress, leading to long-term impairment similar to the lasting effects of Severe Acute Respiratory Syndrome (SARS).   The study will c...